Skip to main content
. 2021 Aug 9;12:705096. doi: 10.3389/fimmu.2021.705096

Figure 3.

Figure 3

The NMA results of the indirect efficacy comparison of anti–PD-1-based therapy and SoC with anti–PD-L1-based therapy in all the available subgroups: (A) age, (B) sex, (C) ECOG PS, (D) smoke habit, (E) type of disease, (F) HPV status.